Emergent BioSolutions (EBS) Total Non-Current Liabilities (2010 - 2026)

Emergent BioSolutions' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $755.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 9.83% year-over-year to $755.6 million; the TTM figure through Mar 2026 stood at $755.6 million (down 9.83% YoY), while the FY2025 annual figure was $742.1 million, down 14.48% from the prior year.
• Total Non-Current Liabilities was $755.6 million for Q1 2026 at Emergent BioSolutions, up from $742.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.7 billion in Q4 2022 to a low of $742.1 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 43.51% in 2023, then slumped 35.48% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $1.7 billion in 2022, then tumbled by 34.09% to $1.1 billion in 2023, then declined by 24.21% to $867.8 million in 2024, then retreated by 14.48% to $742.1 million in 2025, then grew by 1.82% to $755.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $755.6 million (Q1 2026), $742.1 million (Q4 2025), and $835.9 million (Q3 2025), per Business Quant data.